for males ages 18 years and up (full criteria)
study started
completion around



The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse. Participation may last approximately 60 months.

Official Title

CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer


Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Metastatic Hormone Sensitive Prostate Cancer, mHSPC, Stage IV Prostate Cancer, Recurrent Prostate Cancer, De Novo Metastatic Prostate Cancer, High-Risk, Visceral metastasis, Cyclin-Dependent Kinase 4 (CDK4), Cyclin-Dependent Kinase 6 (CDK6), CDK4, CDK6, CDK4/6, Neoplasms, Hypersensitivity, Abemaciclib, Abiraterone, Prednisone or Prednisolone, Abemaciclib + Abiraterone + Prednisone/Prednisolone


You can join if…

Open to males ages 18 years and up

  • Adenocarcinoma of the prostate (as the predominant histology)
  • High-risk metastatic hormone-sensitive prostate cancer. High risk is defined as:
  • Must have initiated androgen deprivation therapy (ADT) with luteinizing hormone-releasing hormone (LHRH) agonist/antagonist or bilateral orchiectomy prior to randomization. Up to 3 months of ADT prior to randomization is permitted with or without first-generation anti-androgen.
  • Adequate organ function
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

You CAN'T join if...

  • Prior treatment with abemaciclib or any other cyclin dependent kinase 4 and 6 (CDK4 & 6) inhibitor
  • Development of metastatic prostate cancer in the context of castrate levels of testosterone
  • Received any prior systemic therapy for metastatic prostate cancer (including investigational agents), except for ADT and first-generation anti-androgen
  • Clinically significant cardiovascular disease as evidenced by myocardial infarction, arterial thrombotic events, or severe/unstable angina in the past 6 months, or New York Heart Association Class II to IV heart failure
  • History of syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin, or sudden cardiac arrest. Chronic and hemodynamically stable atrial arrhythmia well-controlled on medical therapy is permitted
  • Uncontrolled hypertension
  • Clinically active or chronic liver disease, moderate/severe hepatic impairment
  • Known untreated central nervous system (CNS) metastasis. Participants with a history of treated brain metastases are eligible if stable for at least 8 weeks prior to randomization and off corticosteroid for at least 2 weeks prior to randomization


  • UCLA Hematology/Oncology - Santa Monica
    Los Angeles California 90404 United States
  • Moores Cancer Center
    La Jolla California 92093 United States
  • Orange Coast Memorial Medical Center
    Fountain Valley California 92708 United States
  • Cancer and Blood Specialty Clinic
    Los Alamitos California 90720 United States
  • Torrance Memorial Physician Network / Cancer Care
    Torrance California 90505 United States
  • Providence Medical Foundation
    Fullerton California 92835 United States
  • MemorialCare Health System - Long Beach Medical Center
    Long Beach California 90806 United States
  • PIH Health Hematology Medical Oncology
    Whittier California 90602 United States


in progress, not accepting new patients
Start Date
Completion Date
Eli Lilly and Company
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) (CYCLONE 3)
Phase 3 research study
Study Type
Expecting 900 study participants
Last Updated